SCHEMBL6320135

SCHEMBL6320135

CS(=O)(=O)N(CC(=O)O)c1ccc(NC(=C2C(=O)Nc3ccccc32)c2ccccc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.45
KMT2A Q03164 2/20 0.42
TSHR P16473 1/20 0.42
LMNA P02545 2/20 0.39
GAA P10253 1/20 0.39
NPC1 O15118 2/20 0.39
POLB P06746 1/20 0.39
RAB9A P51151 1/20 0.39
ALDH1A1 P00352 3/20 0.38
MAPT P10636 2/20 0.38
IDO1 P14902 2/20 0.38
TDO2 P48775 1/20 0.38
MMP2 P08253 1/20 0.38
MMP9 P14780 1/20 0.38
MEN1 O00255 1/20 0.37
KDR P35968 1/20 0.37
PHGDH O43175 1/20 0.36
PTPN1 P18031 1/20 0.36
PTPN6 P29350 1/20 0.36
PTPN11 Q06124 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6320129 1.00 SMN1; SMN2 (0.45) SMN1; SMN2KMT2ATSHRLMNAGAA
SCHEMBL6319738 0.92 KMT2A (0.41) SMN1; SMN2KMT2ATSHRLMNAGAA
SCHEMBL6319740 0.92 KMT2A (0.41) SMN1; SMN2KMT2ATSHRLMNAGAA
SCHEMBL6320026 0.92 KMT2A (0.40) SMN1; SMN2KMT2ATSHRLMNAGAA
SCHEMBL6320028 0.92 KMT2A (0.40) SMN1; SMN2KMT2ATSHRLMNAGAA
SCHEMBL6320845 0.92 KMT2A (0.45) SMN1; SMN2KMT2ATSHRLMNAGAA
SCHEMBL6318824 0.92 KMT2A (0.45) SMN1; SMN2KMT2ATSHRLMNAGAA
SCHEMBL6320337 0.91 IDO1 (0.39) SMN1; SMN2KMT2AGAANPC1POLB
SCHEMBL6320327 0.91 IDO1 (0.39) SMN1; SMN2KMT2AGAANPC1POLB
SCHEMBL6318712 0.90 KMT2A (0.49) SMN1; SMN2KMT2ATSHRLMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6855710-B2 Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-02-15 US disclosed
US-20040058978-A1 Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-03-25 US disclosed
EP-1115704-B1 NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES BOEHRINGER INGELHEIM PHARMA (DE) 2003-06-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058978-A1 Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs CDK1, CDK2, CDK3 SMN1; SMN2 4425/4885KMT2A 750/4885TSHR 1247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.